Skip to content

    GlaxoSmithKline Pharmaceuticals Limited

    GLAXO
    Healthcare·13 May 2025
    Management Summary

    GlaxoSmithKline Pharmaceuticals reported a strong Q4 and full year FY25, with full year revenue growing 9% to INR 3723 crores and EBITDA up 30% to INR 1169 crores, driven by volume growth and margin expansion. The company successfully launched Shingrix, achieving 10,000 doses in March, and is preparing for oncology launches (Jemperli and Zejula). Despite a soft quarter for antibiotics and stunted growth in acute segments, the specialty and derms portfolios showed robust double-digit growth, supported by an enhanced digital strategy reaching over 400,000 HCPs.

    Highlights

    10

    • Full year revenue of INR 3723 crores, up 9% YoY.

    • Full year EBITDA of INR 1169 crores, up 30% YoY, with margins expanding from 26% to 31% YoY.

    • Full year PAT grew 32% and EPS grew 32%.

    • Q4 revenue grew 6%, Q4 EBITDA grew 30%, and Q4 PAT grew 36%.

    • Specialty segment grew 35% for the full year, and pediatric vaccines grew 12%.

    • Shingrix sales reached 10,000 doses in March 2025, with almost 20,000 doses in Q4.

    • Oncology products Jemperli and Zejula received marketing authorization and are set for launch in the coming months.

    • Company maintains a zero-debt status with INR 2,500 crores cash.

    • Derms business grew in double digits for the quarter and is the number one player in the segment.

    • Digital strategy led to over 400,000 unique HCP touchpoints, increasing reach by over 40%.

    Concerns

    4

    • External landscape did not evolve as expected in Q4, leading to stunted growth in acute segments of the Indian pharmaceutical market.

    • Anti-infectives portfolio experienced suppressed external growth of just about 3%.

    • Antibiotics had a soft quarter.

    • The company does not expect a significant upward change in the sustainable full-year margin of 31.4%.

    What Changed2

    vs Q3 FY26

    Guidance items8 → 6 (-2)Risks discussed2 → 3 (+1)
    Key financials

    Metrics

    8

    Periods

    2

    Headline

    5
    • Revenue (Full Year)
      ₹3,723 Cr
      YoY+9%
    • EBITDA (Full Year)
      ₹1,169 Cr
      YoY+30%
    • EBITDA Margin (Full Year)
      31%
    • PAT Growth (Full Year)
      —
      YoY+32%
    • EPS Growth (Full Year)
      —
      YoY+32%

    Q4

    3
    • Revenue Growth
      —
      YoY+6%
    • EBITDA Growth
      —
      YoY+30%
    • PAT Growth
      —
      YoY+36%

    Segment breakdown

    General Medicine (Full Year)
    8% Volume Growth
    Specialty Segment (Full Year)
    35% Growth
    Pediatric Vaccines (Full Year)
    12% Growth
    Pediatric Vaccines (Q4)
    10% Growth
    Anti-infectives (Q4)
    3% External Growth
    Derms Business (Q4)
    — Growth
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Debt

    Debt disclosed

    Dividend

    ₹42/share (final)

    Liquidity

    Cash ₹2,500 crores

    Guidance & targets

    6
    CategoryTargetPriority
    Profitability
    EBITDA Margin (Full Year)
    31.4%
    		High
    Revenue
    Revenue Growth
    above 8-9% (double digit)
    		High
    Product Launch
    Oncology Product Launches
    Jemperli and Zejula
    		High
    Product Launch
    Drug Launch Lag
    reduced
    		Medium
    Product Launch
    RSV Vaccine Trials
    ongoing in India
    		High
    Strategy
    Growth Driver
    volume-led
    		High

    What to watch in Q1 FY26

    4

    Progress of oncology launches (Jemperli, Zejula)

    Next quarter / Coming months
    CurrentMarketing authorization received, set to launch in coming months.
    TargetInitial launch traction, patient reach, early revenue contribution.

    Why it matters

    These are new growth drivers and represent the company's entry into the high-growth oncology segment.

    we have the marketing authorization for two of our global assets; Dostarlimab which is the brand - the trademark is Jemperli and Niraparib, which is Zejula, respectively, in gynecological malignancy. So, those are the first two ones, which will go off the block in terms of a long sequence in this coming financial year.

    Risks & concerns

    3
    RiskSeverity

    Stunted growth in acute segments of the Indian pharmaceutical market

    The external landscape did not evolve as expected, leading to stunted growth, especially around acute segments of the Indian pharmaceutical market. — Management acknowledged

    medium

    Suppressed external growth in the anti-infectives portfolio

    The anti-infectives portfolio experienced suppressed external growth of just about 3%. — Management acknowledged

    medium

    Changing regulations and government push for generic medicines

    Hearings are ongoing in the Supreme Court regarding generic medicine promotion, which the company is monitoring. — Analyst acknowledged

    medium

    Q&A highlights

    7

    “for guidance, you might have to take the full year margin, which is a bit of margin of 31.4. This is what we are tracking as a sustainable margin. Now, you might have noticed the margin profile has gone up significantly, a lot of low hanging fruit. So, lots of changes we have made and we are at a perhaps at a stabilization stage. So, at this stage, you should not expect a big change in the margin profile upwards.”

    Clarifies that the 31.4% full-year EBITDA margin is considered sustainable and further significant expansion is not expected, setting investor expectations.

    asked by Pritesh Chheda

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Full Year FY25 Performance Driven by Volume and Margin Expansion

    GlaxoSmithKline Pharmaceuticals reported a robust full year FY25, with revenue reaching INR 3723 crores, marking a 9% year-on-year growth. EBITDA surged by 30% to INR 1169 crores, and EBITDA margins expanded significantly from 26% in the previous year to 31%. This performance was primarily volume-led, with general medicines volume growing 8% and specialty segment revenue increasing by 35%.

    02

    Q4 FY25 Performance Amidst Market Challenges

    For Q4 FY25, the company recorded a 6% revenue growth, a 30% increase in EBITDA, and a 36% rise in PAT. This was achieved despite a 'soft quarter' for antibiotics and 'stunted growth' in the acute segments of the Indian pharmaceutical market, where the anti-infectives portfolio saw suppressed external growth of just about 3%. Pediatric vaccines, however, maintained strong momentum with 10% growth in the quarter.

    03

    New Growth Platforms: Oncology and Respiratory

    The company is actively building new growth platforms, particularly in oncology and respiratory. Marketing authorization has been secured for two global oncology assets, Jemperli (for endometrial cancer) and Zejula (for ovarian cancer), with launches anticipated in the coming months⏳. In the respiratory segment, Trelegy and Nucala currently contribute INR 120-130 crores in annual revenues, with Trelegy identified as a key growth driver.

    04

    Shingrix and Adult Vaccination Ecosystem

    Shingrix, the shingles vaccine, demonstrated strong traction, with almost 20,000 doses administered in Q4 FY25, including 10,000 doses in March alone. The company is focused on 'market shaping' to build an adult vaccination ecosystem, targeting 10-12 million Indians over 50 years of age who are eligible for prevention. Additionally, trials are ongoing in India for an RSV vaccine, which is expected to be the next adult vaccine.

    05

    Digital Transformation and Enhanced HCP Reach

    GlaxoSmithKline Pharmaceuticals has significantly advanced its digital strategy, leading to a substantial increase in healthcare practitioner (HCP) engagement. Through its omni-channel and digital initiatives, the company now reaches approximately 275,000 distinct unique HCPs, with over 400,000 unique HCP touchpoints. This digital transformation has increased the company's reach by over 40% compared to previous periods, complementing its optimized field force.

    06

    Sustainable Margins and Volume-Led Strategy

    The company's full-year EBITDA margin of 31.4% is considered sustainable, with management not expecting significant upward changes. The strategy remains largely volume-led, especially given that over half of the general medicines portfolio is under price control. While price increases are taken in the 60% non-NLEM portfolio where competitive, the focus is on driving volumes and maintaining market share.

    07

    Manufacturing and Regulatory Landscape

    GlaxoSmithKline Pharmaceuticals operates its own manufacturing site in Nashik, which contributes over one-third of its top-line revenues for general medicines, and partners with 20 CMOs for the remaining 99% of its locally manufactured portfolio. The company is actively involved in 19 global clinical trials in India across oncology and hepatology, aiming to reduce drug launch lag. Management is monitoring ongoing Supreme Court hearings regarding generic medicine promotion, emphasizing evidence-based prescribing and the Uniform Code of Pharmaceutical Marketing Practices.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.